Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of MannKind
So what: The news of the day was the FDA delayed its decision on inhaled insulin product Afrezza until around Jan. 26. Analysts are having a tough time figuring out if this is bearish or bullish news, but the bulls took hold early this morning.
Now what: Bulls are interpreting it as a sign the FDA is diligently looking at the application and just needs more time to review the latest information. Bears see this as a sign the FDA doesn't think Afrezza is urgent. Today's news doesn't appear to provide a lot of conviction one way or the other. I don't think today should change your opinion going forward; it just delays the verdict everyone wants to hear.
Interested in more info on MannKind? Add it to your watchlist.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Here's Why MannKind Corporation Remained Stuck in Reverse and Lost 24% in February
MannKind's reverse stock split gave investors the blues.
Why MannKind Corporation Stock Is Sinking Today
The biopharma's reverse split isn't a hit with investors.
3 Stocks to Avoid in Biotech
Biotech stocks are known for their high growth, but they can also be toxic for your portfolio if you don't invest wisely.